Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Oxaliplatin is a platinum analogue that has significant antitumor activity with better
tolerability than cisplatin. The objective of the study is to evaluate the safety and
activity of leucovorin and 5-fluorouracil and leucovorin and 5-fluorouracil plus oxaliplatin
combination chemotherapy given as adjuvant therapy for curatively-resected, node-positive
esophageal cancer.